Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia

A. Lindemann; Karin Kolbe; H. G. Fuhr; F. Rosenthal; G. Küsters; F. Herrmann; K. Höffken; R Mertelsmann

doi:10.1007/978-3-642-75720-4_2

ScienceGate Book Chapters

BOOK-CHAPTER

Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia

A. Lindemann Karin Kolbe H. G. Fuhr F. Rosenthal G. Küsters F. Herrmann K. Höffken R Mertelsmann

Year: 1990 Pages: 9-18

DOI: 10.1007/978-3-642-75720-4_2

Get Full-Text PDF Get Analytical Report

Keywords:

Refractory (planetary science) Medicine Mitoxantrone Toxicity Aclarubicin Leukemia Gastroenterology Cytarabine Internal medicine Pharmacology Chemotherapy Materials science

Metrics

Cited By

0.00

FWCI (Field Weighted Citation Impact)

Refs

0.05

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Topics

Cancer therapeutics and mechanisms

Life Sciences → Biochemistry, Genetics and Molecular Biology → Molecular Biology

Pneumocystis jirovecii pneumonia detection and treatment

Health Sciences → Medicine → Epidemiology

Acute Myeloid Leukemia Research

Health Sciences → Medicine → Hematology

Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia

Metrics

Topics

Related Documents

Low-dose cytosine arabinoside in relapsed acute lymphocytic leukemia

Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia

Intermediate-Dose Cytosine Arabinoside and Amsacrine for Remission Induction and High-Dose Cytosine Arabinoside and Amsacrine for Intensive Consolidation in Relapsed and Refractory Adult Acute Myelogenous Leukemia

Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia

Sequential intermediate‐dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia